All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: May 1, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

28

2023 to 2026

Breakthrough

1

Accelerated

0

Priority review

3

Orphan

3

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202316
202417
202527
202631

28 approvals

Newest first. Hover a badge for what it means.

  • Jakafi Xr (Ruxolitinib Phosphate) · Incyte CorpMay 1, 2026
    Original approval · NDA 217180OrphanApproval letter
  • Icotyde (Icotrokinra Hydrochloride) · Janssen BiotechMar 17, 2026
    Original approval · NDA 220149NovelPriority reviewApproval letter

    To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy

  • Adquey (Difamilast) · Acrotech BiopharmaFeb 12, 2026
    Original approval · NDA 219474NovelApproval letter

    To treat mild to moderate atopic dermatitis

  • Avtozma (Tocilizumab-Anoh) · Celltrion INCJan 21, 2026
    Original approval · BLA 761498Approval letter
  • Rhapsido (Remibrutinib) · NovartisSep 30, 2025
    Original approval · NDA 218436NovelPriority reviewApproval letter

    To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment

  • Anzupgo (Delgocitinib) · Leo Pharma AsJul 23, 2025
    Original approval · NDA 219155NovelApproval letter

    To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response

  • Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTDMay 22, 2025
    Original approval · BLA 761419Approval letter
  • Steqeyma (Ustekinumab-Stba) · Celltrion, Inc.Apr 30, 2025
    Original approval · BLA 761338Approval letter
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025
    Original approval · BLA 761373Approval letter
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025
    Original approval · BLA 761425Approval letter
  • Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USAApr 30, 2025
    Original approval · BLA 761379Approval letter
  • Tyenne (Tocilizumab-Aazg) · Fresenius Kabi USAMar 14, 2025
    Original approval · BLA 761449Approval letter
  • Avtozma (Tocilizumab-Anoh) · Celltrion INCJan 24, 2025
    Original approval · BLA 761420Approval letter
  • Steqeyma (Ustekinumab-Stba) · Celltrion, Inc.Dec 17, 2024
    Original approval · BLA 761338Approval letter
  • Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USASep 27, 2024
    Original approval · BLA 761379Approval letter
  • Ebglyss (Lebrikizumab-Lbkz) · Eli Lilly and COSep 13, 2024
    Original approval · BLA 761306NovelApproval letter

    To treat moderate-to-severe atopic dermatitis

  • Nemluvio (Nemolizumab-Ilto) · Galderma Labs LpAug 12, 2024
    Original approval · BLA 761390NovelBreakthrough therapyPriority reviewApproval letter

    To treat prurigo nodularis

  • Leqselvi (Deuruxolitinib Phosphate) · Sun Pharm Inds INCJul 25, 2024
    Original approval · NDA 217900NovelApproval letter

    To treat severe alopecia areata

  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024
    Original approval · BLA 761373Approval letter
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024
    Original approval · BLA 761425Approval letter
  • Tyenne (Tocilizumab-Aazg) · Fresenius Kabi USAMar 5, 2024
    Original approval · BLA 761275OrphanApproval letter
  • Wezlana (Ustekinumab-Auub) · Amgen INCOct 31, 2023
    Original approval · BLA 761285Approval letter
  • Wezlana (Ustekinumab-Auub) · Amgen INCOct 31, 2023
    Original approval · BLA 761331Approval letter
  • Omvoh (Mirikizumab-Mrkz) · Eli Lilly and COOct 26, 2023
    Original approval · BLA 761279NovelOrphanApproval letter

    To treat ulcerative colitis

  • Bimzelx (Bimekizumab-Bkzx) · Ucb INCOct 17, 2023
    Original approval · BLA 761151NovelApproval letter

    To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

  • Velsipity (Etrasimod Arginine) · PfizerOct 12, 2023
    Original approval · NDA 216956NovelApproval letter

    To treat moderately to severely active ulcerative colitis in adults

  • Cosentyx (Secukinumab) · Novartis Pharms CorpOct 6, 2023
    Original approval · BLA 761349Approval letter
  • Tofidence (Tocilizumab-Bavi) · Biogen MaSep 29, 2023
    Original approval · BLA 761354Approval letter

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.